Navigation Links
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
Date:6/13/2008

Data Presented at the European Cystic Fibrosis Society Conference

MONMOUTH JUNCTION, N.J., June 13 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace(TM) (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis (CF) patients who have lung infections due to the bacterium Pseudomonas aeruginosa. The Phase II data indicated that Arikace, delivered once daily for 28 consecutive days, produced a significant improvement in lung function, was well-tolerated, and had a side-effect profile comparable to placebo. The Phase II trial was a randomized, double-blind, placebo-controlled study of 64 patients from 15 centers in Europe. Results were presented today at the 31st European Cystic Fibrosis Society (ECFS) Conference in Prague, Czech Republic, by Lieven Dupont, MD, Associate Professor of Respiratory Medicine at the Katholieke Universiteit, Leuven, Belgium, and co-lead investigator of the study.

Arikace is a novel molecular entity comprised of the antibiotic amikacin, which is enclosed in nanocapsules of lipids called liposomes. Arikace was administered once daily for 28 days at 280 mg and 560 mg dosages, using a novel inhalation device, the eFlow(R) Electronic Nebulizer (PARI Pharma GmbH).

The intent-to-treat analysis for efficacy demonstrated that Arikace, when administered once daily either at 280 mg or 560 mg for 28 days, resulted in clinically significant improvement in lung function at the end of treatment. This improvement was dose-dependent and was sustained at 28 days after completion of dosing, which was day 56 of the study. Pulmonary function (FEV1) increased significantly among patients receiving the 560 mg dose of Arikace, with a sustained treatment effect of 224 ml (p=0.004) and 17.6% (p=0.009) increase compared to placebo, at day 56.

Arikace was well tolerated, with no differences observed in
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
2. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
3. XTENT Announces European Regulatory Update
4. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
5. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
6. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
7. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
8. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
9. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
10. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
11. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The Natural ... the dietary supplement and natural products industry. NPA ... Corey Hilmas , M.D., Ph.D., former Chief ... the Division of Dietary Supplement Programs at the ... that claims to link dietary supplement intake with ...
(Date:4/21/2015)... DUBLIN , April 21, 2015  Perrigo Company ... that its Board of Directors has unanimously rejected the ... MYL ), disclosed April 8, 2015, to acquire ... per share. Following a thorough review, advised by its ... the Proposal substantially undervalues the Company and its future ...
(Date:4/21/2015)... 2015  CorTechs Labs, der führende Innovator ... Hirnvolumens freut sich, eine Partnerschaft mit Novartis ... zu können. Die Unternehmen werden bei der ... der die Identifizierung, Messung und Nachverfolgung des ... Sklerose als Ziel hat. Der ...
Breaking Medicine Technology:NPA Chief Scientist Comments on Research Associating Dietary Supplements with Increased Cancer Risk 2NPA Chief Scientist Comments on Research Associating Dietary Supplements with Increased Cancer Risk 3Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 2Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 3Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 4Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 5Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 6Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 7Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 8Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 9CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2
... Hologic, Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics, medical imaging systems and surgical products ... announced plans to release its fourth quarter fiscal 2011 ... conjunction with the release, management will host a conference ...
... VIEW, Calif., Sept. 27, 2011 AccessClosure, Inc., a ... shipment of its one millionth Mynx unit. The Mynx ... 2007, following with its full commercial launch in September ... milestone to the fact that the Mynx sealant is ...
Cached Medicine Technology:Hologic to Release Fourth Quarter Fiscal 2011 Operating Results on Monday, November 7, 2011 2AccessClosure, Inc. Marches to the Millionth Mynx! 2
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... than 275 leading life sciences organizations, released the ... Radcliffe regarding California State Assembly Bill (AB) 463: ... dedicated to the development of treatments and cures ... have deep concerns regarding AB 463, the so-called ...
(Date:4/21/2015)... 2015 Angelo’s FabriClean has recently announced ... for clients that avail the area rug cleaning services. ... done with hi-tech equipments, making use of the quick ... all natural, high pressure steam extraction to clean even ... for area rugs made with delicate fabric. , ...
(Date:4/21/2015)... Wireless Analytics, LLC , a pioneering provider ... Boston Business Journal as the 25th fastest-growing private company ... recent event celebrating the 2015 Pacesetters, the Boston ... in Massachusetts. , Wireless Analytics was ranked among 70 ... fastest revenue growth from 2011 through 2014. This ...
(Date:4/21/2015)... Lyft has announced the availability ... bringing the most advanced speech-recognition technology to another ... can now experience the full benefits of a ... the industry, Lyft, which offers value-added support services ... “Lyft is very excited to be able to ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Carinsurancehints.com has ... roads and explaining their impact on auto insurance ... can increase auto insurance prices. Clients should review their ... insurance can be bought under several forms. Some of ... , rivers can compare online rates and find ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2
... New MEDEX Global Group/Harvard Medical International Website goes beyond, ... the Lesser-Known Factors ... Healthcare, BALTIMORE, Nov. 29 Determining health risks ... incredibly complex.,According to the just published MEDEX 360m International ...
... patient he was,treating in the Yale University-affiliated community health ... thought he could almost be looking in a,mirror. The ... near,Graham,s own home in New Haven, Conn., (Photo: ... Graham,s good health, the man was coughing,feverish, and losing ...
... Understanding the needs of minority communities is key, ... News) -- Collaborations between researchers and community groups ... researchers report. , They based their conclusions on ... Tenn. and among the Navajo Nation. , Such ...
... Scientists from the National Cancer Institute are looking into ... breast cancer tumors and are presenting their findings this ... on The Science of Cancer Health Disparities in Racial/Ethnic ... in Atlanta. , While observed differences in ...
... level of Quitline smoking cessation services and offering free ... reduce smoking rates, according to two new studies in ... of the British Medical Journal. Both studies were conducted ... in Portland, the Oregon Health Department, and Free & ...
... HARRISBURG, Pa., Nov. 29 As part of ... Health Dr. Calvin Johnson and,Secretary of Public Welfare Estelle ... -- the virus that causes AIDS. They also highlighted,ongoing ... how it is,prevented., "Our message is clear: regardless ...
Cached Medicine News:Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:Take the Test, Take Control: World AIDS Day 2007 2Health News:Research Can Help Close Cancer 'Race Gap' 2Health News:Research Can Help Close Cancer 'Race Gap' 3Health News:Racial and ethnic differences in the biology of breast cancer tumors 2Health News:Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches 2Health News:Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches 3Health News:Secretaries of Health and Public Welfare Recognize World Aids Day; Urge HIV-Testing 2
Provides a combination of concentrated cold / hot and compression for the shoulder...
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Universal Cervical Collar has medium density foam and contact closure for easy fit....
... with optional hot and cold therapy Gel Pad. ... by providing cold therapy to reduce swelling and ... stimulate recovery., ,To order hot and cold ... item number., ,Our suspenders can be added ...
Medicine Products: